Imatinib in gastrointestinal stromal tumors

Journal of Association of Physicians of India

Volumn 52, Issue MAY, 2004, Pages 403-409

  Bakshi, C A ^a   Jain, R A ^a   Sastry, P S R K ^a   Sainani, A R ^a   Advani, S H ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 13944273053     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Miettinen M, El-Rifai W, Sobin H L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumours: a review. Human Pathology 2002; 33:478-83.
2. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors, Lancet Oncology 2002;3:655-64.
3. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121
4. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
5. Goss GA, Merriam P, Manola J, Singer S, Fletcher CD, Demetri GD. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST). Prog Proc Am Soc Clin Oncol 2000;19:599a. abstract.
6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
7. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
8. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Oh KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96: 925-32.
9. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-3528.
10. Bapsy PP, Prabhash K, Babu KG, et al. Gastrointestinal stromal tumour - A paradigm shift in management of solid tumours. J Assoc Physicians India 2003;51:801-4.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056
12. Denatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumours: before and after STI-571. Human Pathology 2002;33:466-77.
13. Blanke CD, von Mehren M, Joensuu H et al: Evaluation of the safety and efficacy of an oral molecularly targeted therapy, STI 571, in patients with unresectable or metastatic gastrointestinal stromal tumours (GISTs) expressing C-kit (CD 117). Prog Proc Am Soc Clin Oncol 2001; 20: 1a. abstract.
14. Demetri DG, Mehren VM, Blanke CD, Efficacy and safety of Glivec mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002;347: 472-80.
15. Van Oosterom AT, Judson I, Verweji J, et al: Safety and efficacy of Glivec (STI 571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.